Ken Griffin Innate Pharma Sa Call Options Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IPHA
# of Institutions
11Shares Held
127KCall Options Held
0Put Options Held
0-
Exchange Traded Concepts, LLC62.8KShares$139,9360.0% of portfolio
-
Morgan Stanley New York, NY43.5KShares$97,0580.0% of portfolio
-
Gamma Investing LLC Foster City, CA3.98KShares$8,8640.01% of portfolio
-
Ubs Group Ag3.51KShares$7,8270.0% of portfolio
-
Rhumbline Advisers Boston, MA675Shares$1,5050.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $178M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...